A Multicenter, Clinical Phase II study of FOLFOXIRI with Bevacizumab As First-line Therapy in Patients with Metastatic Colorectal Cancer.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 May 2016
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Camptothecin; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 28 Aug 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
- 27 Jun 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 25 Apr 2014 New trial record